
Quotient Sciences
Building a best-in-class pharmaceutical services business, Quotient Sciences takes an innovative approach to drug development.
Through its unique Translational Pharmaceutics platform, Quotient can accelerate the drug development process, enabling its pharmaceutical and biotech customers to reduce the time and cost of bringing a new drug to market.
Through its unique Translational Pharmaceutics platform, Quotient can accelerate the drug development process, enabling its pharmaceutical and biotech customers to reduce the time and cost of bringing a new drug to market.
2019
Investment year
£140m+
Annual revenues
275+
Molecules
Related News & Insights

News
17 Sep 2026
Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation in Clinical Study

News
28 May 2026
Quotient Sciences Advances AI-Designed Drug Product into Clinical Development


News
26 Feb 2026
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment

News
4 Dec 2025
Quotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation development

News
14 Oct 2025
Quotient Sciences and Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof of Concept

News
2 Sep 2025
Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture


News
3 Mar 2025
Quotient Sciences completes project to improve high potency handling at Philadelphia, Pa. facility


News
28 Oct 2024
Thierry Van Nieuwenhove Shares His Insights on Emerging Trends in the CDMO Industry


News
16 Dec 2022
HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

News
1 Dec 2022
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03

News
29 Sep 2022
Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

News
23 Sep 2022
Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs


News
31 Aug 2022
Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose


News
13 Jun 2022
Quotient Sciences Completes Integration of Drugs Substance into Translational Pharmaceutics® Platform

News
25 Aug 2021
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility

News
9 Feb 2021
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization

News
11 Aug 2020
ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

News
28 Apr 2020
Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

Reporting









